Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors

This comparative-effectiveness study of 48,165 individuals with type 2 diabetes initiating second-line therapy found that treatment with glipizide was associated with a modestly higher 5-year risk of major adverse cardiovascular events compared to DPP-4 inhibitors.